Letters to the editor

Calprotectin alone is not sufficient to predict response to methotrexate in early ACR/EULAR 2010 rheumatoid arthritis: Analysis of the ESPOIR cohort

Keywords:
DMARDs
Early rheumatoid arthritis
Inflammation

Methotrexate (MTX) remains the cornerstone of RA (Rheumatoid arthritis) treatment according to EULAR (European League Against Rheumatism) recommendations [1]. However, theragnostic tools, which help to better identify responders to MTX, are scarce [2,3]. Calprotectin is a neutrophil-related protein which is locally released in inflammatory joints in contrast with CRP (Creative protein). Calprotectin has been suggested as a biomarker for structural damage prediction in RA [4].

We conducted a post-hoc analysis of prospective ESPOIR cohort [5], NCT03666091, of early arthritis on patients from 18 to 70 years old, with 2 or more inflammatory arthritis for a period lasting between 6 weeks and 6 months, in order to assess whether baseline serum calprotectin levels would be predictive of a good EULAR response to MTX. We included patients (i) who fulfilled the 2010 EULAR criteria for RA at baseline, (ii) with a baseline DAS28 > 3.2, (iii) were naive from any DMARD or corticosteroids and (iv) who were treated with monotherapy MTX, oral route, with a dose superior of 0.15 mg/kg/week for at least 6 months. Primary outcome measure was EULAR good response. A total of 98 patients fulfilling the inclusion criteria were analyzed Fig. S1. A total of 48 patients (49%) were classified as responders upon 6 months of MTX treatment. Responders were significantly younger (Table 1). A Youden approach determined a threshold of 446 mg/l, calprotectin was a predictive marker for good EULAR response to MTX, Odds Ratio (OR) 2.8, 95% confidence interval (CI) [1.2, 6.8], P = 0.024, (area under the curve of 0.61). Likewise, age under 47 was predictive of a good response to MTX, OR 2.5, 95%CI [1.1, 5.9], P = 0.005. The multivariable model including potential predictive factors presenting a P-value < 0.2 in the univariate analysis showed that calprotectin and age displayed a sensitivity of 0.54, 95%CI [0.39, 0.69] and specificity of 0.76, 95%CI [0.62, 0.87] (Fig. 1). The multivariable model including CRP did not add any predictive value.

Despite the fact that MTX is the first line treatment of RA, few studies have investigated predictive markers of clinical response to MTX. Age has been reported as a predictive factor in a study [2] but not in another [3]. Even MTX polyglutamate metabolites failed to predict disease activity in patients with RA who were receiving long-term MTX therapy [6]. We included a broad spectrum of early RA patients in order to study real-life settings. Another strength of our study is the large number of covariates collected in the ESPOIR cohort, which minimized the risk of bias. A few limits should be emphasized. First, we excluded from our analysis patients who withdrew MTX because of side effects in order to focus on MTX efficacy. Second, we aimed at characterizing predictive factors of response to MTX when first prescribed according to international recommendations. Therefore, we did not include patients starting MTX with low dose, which explains why a large number of patients of the ESPOIR cohort were discarded from our analysis. Nevertheless, calprotectin was not predictive amongst those patients. The results of our study suggest the potential interest of a multivariable score including calprotectin and age as a tool for personalized medicine in early RA management.

Funding

An unrestricted grant from Merck Sharp and Dohme (MSD) was allocated for the first 5 years. Two additional grants from Inserm

Table 1

Baseline characteristics.

<table>
<thead>
<tr>
<th>Total (n = 98)</th>
<th>Responders (n = 48)</th>
<th>Non-responders (n = 50)</th>
<th>P-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Women, n (%)</td>
<td>80 (82)</td>
<td>36 (75)</td>
<td>0.2</td>
</tr>
<tr>
<td>Age, years</td>
<td>50.6 (39.4–56.4)</td>
<td>46.4 (37.4–55.3)</td>
<td>0.03</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>23.1 (20.4–25.3)</td>
<td>22.2 (20.5–24.7)</td>
<td>0.4</td>
</tr>
<tr>
<td>DAS28-ESR</td>
<td>5.4 (4.7–6)</td>
<td>5.4 (4.7–5.9)</td>
<td>0.9</td>
</tr>
<tr>
<td>ESR, mm/h</td>
<td>24.0 (14.0–39.5)</td>
<td>27.5 (14–36.5)</td>
<td>0.05</td>
</tr>
<tr>
<td>CRP, mg/l</td>
<td>9.0 (7.5–4.8)</td>
<td>11.0 (4–26.5)</td>
<td>0.2</td>
</tr>
<tr>
<td>MTX dose, mg/kg/week</td>
<td>0.20 (0.18–0.24)</td>
<td>0.20 (0.18–0.25)</td>
<td>0.6</td>
</tr>
<tr>
<td>MTX dose, mg/week</td>
<td>12.5 (10–15)</td>
<td>12.5 (10–15)</td>
<td>1</td>
</tr>
<tr>
<td>RF positive, n (%)</td>
<td>57 (58)</td>
<td>28 (58)</td>
<td>1.0</td>
</tr>
<tr>
<td>RF IgM positive, n (%)</td>
<td>61 (62)</td>
<td>29 (60)</td>
<td>0.9</td>
</tr>
<tr>
<td>RF IgA positive, n (%)</td>
<td>55 (56)</td>
<td>24 (50)</td>
<td>0.3</td>
</tr>
<tr>
<td>ACPA positive, n (%)</td>
<td>61 (62)</td>
<td>28 (58)</td>
<td>0.6</td>
</tr>
</tbody>
</table>

*P-values corresponding to Chi² or Wilcoxon tests when appropriate. Patients were considered as ACPA or RF positive when ACPA or RF titer > the upper limit of normal [ULN] for the laboratory and assay; RF: rheumatoid factor; BMI: Body Mass Index; DAS: Disease Activity score; CRP: Creative Protein; MTX: Methotrexate; RF: Rheumatoid Factor; ACPA: Anti-Citrullinated Protein Antibodies; ESR: Erythrocyte Sedimentation Rate. Data are expressed as medians and interquartile range or otherwise stated.

https://doi.org/10.1016/j.jbspin.2019.07.001
1297-319X© 2019 Société française de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.
were obtained to support part of the biological database. The French Society of Rheumatology, Pfizer, Abbvie, Roche-Chugai also supported the ESPOIR cohort study.

**Contribution**

S.L. critically reviewed the study proposal; C.B. critically reviewed the study proposal, A.C. generated statistical analysis and critically reviewed the study proposal; D.W. served as scientific advisor and critically reviewed the study proposal; F.B. served as scientific advisor and critically reviewed the study proposal; M.V.C.N. served as scientific advisor and critically reviewed the study proposal; M.H.P. served as scientific advisor and critically reviewed the study proposal; B.T. served as scientific advisor and critically reviewed the study proposal; P.G. served as scientific advisor and critically reviewed the study proposal; M. V. C. N. served as scientific advisor, collected data, provided and cared for study patients and critically reviewed the study proposal; A.B. served as scientific advisor, collected data, provided and cared for study patients.

**Disclosure of interest**

The authors declare that they have no competing interest.

**Acknowledgements**

Authors thank the Direction de la Recherche Clinique et de l’Innovation of CHU Grenoble-Alpes for its support. We also wish to thank Nathalie Rincheval (CHU de Montpellier and EA 2415) who did expert monitoring and data management and all the investigators who recruited and followed the patients (F. Berenbaum, Paris- Saint Antoine, M.C. Boissier, Paris-Bobigny, A. Cantagrel, Toulouse, B. Combe, Montpellier, M. Dougados, Paris-Cochin, P. Fardelone and P. Boumier Amiens, B. Fautrel, Paris-La Pitié, RM. Flipo, Lille, Ph. Goupille, Tours, F. Liotte, Paris-Lariboisière, O. Vittecoq, Rouen, X. Mariette, Paris Bicêtre, O. Meyer et Ph Dieude, Paris Bichat, A. Saraux, Brest, Th. Schavebeke, Bordeaux, J. Sibilia, Strasbourg); V. Devauchelle and C. Lukas for their expertise in X-ray reading and S. Martin (Paris Bichat) who did all the central dosages of CRP, IgA and IgM rheumatoid factor and anti-CCP antibodies. The authors thank Pr. Bertrand Toussaint and Ms Sylvie Papacatis for her contribution in this study.

**Appendix A. Supplementary data**

Supplementary data associated with this article can be found, in the online version, at https://doi.org/10.1016/j.jbspin.2019.07.001.

**References**


Chloé Bernardy a, b, 1, *, Sophie Lejeune a, 1, Anais Courtier a, Daniel Wendling d, Francis Berenbaum e, Minh Vu Chuong Nguyen b, Philippe Gautdin a, b, Marie Hélène Pactel b,f, Athan Bailler a, b

a Rheumatology department, hôpital Sud, Grenoble Teaching Hospital, CHU de Grenoble-Alpes, Avenue de Kimberley, BP 338, 38434 Échirolles Cedex, France
b University Grenoble-Alpes, GREPI EA7408, 38000 Grenoble, France
c Sinnovial SAS, 38000 Grenoble, France
d Rheumatology department, hôpital Jean-Minjoz, CHRU, 25000 Besançon, France

E-mail address: cbernardy@chu-grenoble.fr

(C. Bernardy)

1 Both authors equally contributed to this work.

Accepted 10 July 2019

Available online xxx